DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for autosomal recessive cerebellar ataxia — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutosomal recessive cerebellar ataxia maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autosomal recessive cerebellar ataxia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tyrosyl-DNA phosphodiesterase 1 (TDP1) — TDP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet k8jdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6N0D · 1.453 Å · ligand 4-fluorobenzene-1,2-dicarboxylic acid (K8J). Experimental structure, not a prediction.
What the evidence adds up to
Autosomal recessive cerebellar ataxias are a group of over 200 genetically heterogeneous conditions that involve degeneration of the cerebellum and associated tracts, leading to impaired balance and coordination. A 2025 review notes that genomic testing now allows rapid identification of most known recessive disorders, shifting research toward targeted mechanistic treatments that address underlying physiological pathways. Molecular classification is being used to identify cellular, biochemical, and genetic targets for precision therapy development. The same review states that ARCAs represent a significant global health burden and that a robust pathway for novel therapeutic discovery is needed, including modification of disease pathogenesis mechanisms and subsequent clinical trial development.
A 2011 review describes the clinical overlap between different cerebellar ataxias, occasional atypical phenotypes, and genetic heterogeneity that complicate clinical management. Despite a steady increase in newly discovered ARCA genes, many patients with a putative ARCA cannot yet be genotyped, indicating that more genes must be involved. That review presents an updated overview of the various ARCAs, discussing clinical and genetic characteristics of forms with a known molecular genetic defect, along with emerging insights into underlying pathophysiological mechanisms.
A 2020 review discusses treatable cerebellar ataxias, noting that a few metabolic, immune mediated, inflammatory and hereditary causes of ataxia can be diagnosed from the gamut of possibilities. It presents a pragmatic algorithm for diagnosing treatable causes of ataxia that includes thorough clinical history, meticulous examination for associated signs, and an investigative approach. The review states that with novel diagnostic techniques and targeted therapies, early diagnosis and treatment can lead to favourable outcomes, but it does not report any specific survival or response rates, nor does it name any drug that has been tested in a controlled trial for ARCAs.
What is still missing are completed clinical trials that test any specific drug in patients with molecularly confirmed ARCAs, funding to move from target identification to phase 2 or 3 studies, and patient stratification strategies that account for the genetic heterogeneity of these disorders. No concrete numbers on survival or response rates are available from these reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 2011 · 46 citations
Autosomal recessive cerebellar ataxias: the current state of affairs
AbstractAmong the hereditary ataxias, autosomal recessive cerebellar ataxias (ARCAs) encompass a diverse group of rare neurodegenerative disorders in which a cerebellar syndrome is the key clinical feature. The clinical overlap between the different cerebellar ataxias, the occasional atypical phenotypes, and the genetic heterogeneity often complicate the clinical management of such patients. Despite the steady increase in newly discovered ARCA genes, many patients with a putative ARCA cannot be genotyped yet, proving that more genes must be involved. This review presents an updated overview of the various ARCAs. The clinical and genetic characteristics of those forms with a known molecular genetic defect are discussed, along with the emerging insights in the underlying pathophysiological mechanisms.
Clinical Parkinsonism & Related Disorders · 2020 · 16 citations · open access
Treatable cerebellar ataxias
AbstractCerebellar ataxic syndrome is a heterogenous class of disorders which can result from a miscellany of causes- genetic or acquired. There are a few metabolic, immune mediated, inflammatory and hereditary causes of ataxia which can be diagnosed from the gamut of possibilities, offering great relief to the ailing patient, their family and the treating physician. A pragmatic algorithm for diagnosing treatable causes of ataxia includes a thorough clinical history, meticulous examination for associated signs and an investigative mind to clinch the diagnosis. With novel diagnostic techniques and targeted therapies, early diagnosis and treatment can lead to favourable outcomes. In this review, diseases presenting predominantly as cerebellar ataxia and are treatable by targeted therapies are discussed.
Annals of Neurology · 2025 · 3 citations · open access
Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies
AbstractAutosomal recessive cerebellar ataxias (ARCAs) represent over 200 clinically heterogeneous genetic conditions involving degeneration of the cerebellum and associated tracts with resultant impairment of balance and coordination. Advancements in genomic testing have enabled rapid identification of the majority of known recessive disorders, shifting research focus to the development of targeted mechanistic treatments addressing underlying physiological pathways. Molecular classification allows recognition of cellular, biochemical, and genetic targets for high-effect precision therapy development. ARCAs represent a significant global health burden, requiring establishment of a robust pathway for novel therapeutic discovery through modification of mechanisms of disease pathogenesis and subsequent clinical trial development. ANN NEUROL 2025;98:448-470.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
